A. Harvey-Langton

Erratum to ‘HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)’

S. Chanalet, M. Ticchioni, C. Pradier, 2017, Heliyon.

HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)

S. Chanalet, M. Ticchioni, C. Pradier, 2017, Heliyon.

Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study

M. Ticchioni, Jacques Durant, C. Pradier, 2013, Journal of NeuroVirology.

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication

M. Ticchioni, Jacques Durant, C. Pradier, 2016, Journal of NeuroVirology.

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

M. Ticchioni, C. Pradier, V. Biscay, 2014, AIDS.

Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study

M. Ticchioni, C. Pradier, C. Lebrun-Frénay, 2013, Journal of NeuroVirology.

Virologically suppressed patients with asymptomatic and symptomatic HIV‐associated neurocognitive disorders do not display the same pattern of immune activation

M. Ticchioni, Jacques Durant, C. Pradier, 2015, HIV medicine.